165 related articles for article (PubMed ID: 36858505)
1. [Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
Nagamine J
Nihon Yakurigaku Zasshi; 2023; 158(2):193-202. PubMed ID: 36858505
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Hallakou-Bozec S; Vial G; Kergoat M; Fouqueray P; Bolze S; Borel AL; Fontaine E; Moller DE
Diabetes Obes Metab; 2021 Mar; 23(3):664-673. PubMed ID: 33269554
[TBL] [Abstract][Full Text] [Related]
3. Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.
Hallakou-Bozec S; Kergoat M; Fouqueray P; Bolze S; Moller DE
PLoS One; 2021; 16(2):e0241651. PubMed ID: 33606677
[TBL] [Abstract][Full Text] [Related]
4. A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway.
Funazaki S; Yoshida M; Yamada H; Kakei M; Kawakami M; Nagashima S; Hara K; Dezaki K
J Diabetes Investig; 2022 Jan; 13(1):34-41. PubMed ID: 34523242
[TBL] [Abstract][Full Text] [Related]
5. Imeglimin: the New Kid on the Block.
Shrestha SC; Gupta S
Curr Diab Rep; 2024 Jan; 24(1):13-18. PubMed ID: 38051432
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Johansson KS; Brønden A; Knop FK; Christensen MB
Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
[TBL] [Abstract][Full Text] [Related]
7. Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules.
Sanada J; Obata A; Fushimi Y; Kimura T; Shimoda M; Ikeda T; Nogami Y; Obata Y; Yamasaki Y; Nakanishi S; Mune T; Kaku K; Kaneto H
Sci Rep; 2022 Aug; 12(1):13220. PubMed ID: 35918386
[TBL] [Abstract][Full Text] [Related]
8. Imeglimin Hydrochloride: First Approval.
Lamb YN
Drugs; 2021 Sep; 81(14):1683-1690. PubMed ID: 34472031
[TBL] [Abstract][Full Text] [Related]
9. Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications.
Yanai H; Adachi H; Hakoshima M; Katsuyama H
Biology (Basel); 2023 May; 12(5):. PubMed ID: 37237539
[TBL] [Abstract][Full Text] [Related]
10. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
Pirags V; Lebovitz H; Fouqueray P
Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
[TBL] [Abstract][Full Text] [Related]
12. [Erratum: Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
Nihon Yakurigaku Zasshi; 2023; 158(4):343. PubMed ID: 38057096
[No Abstract] [Full Text] [Related]
13. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
[TBL] [Abstract][Full Text] [Related]
14. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
[TBL] [Abstract][Full Text] [Related]
15. Imeglimin mitigates the accumulation of dysfunctional mitochondria to restore insulin secretion and suppress apoptosis of pancreatic β-cells from db/db mice.
Aoyagi K; Nishiwaki C; Nakamichi Y; Yamashita SI; Kanki T; Ohara-Imaizumi M
Sci Rep; 2024 Mar; 14(1):6178. PubMed ID: 38485716
[TBL] [Abstract][Full Text] [Related]
16. Exploring new mechanisms of Imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunction.
Li Y; Lou N; Liu X; Zhuang X; Chen S
Biomed Pharmacother; 2024 Jun; 175():116755. PubMed ID: 38772155
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Dubourg J; Ueki K; Grouin JM; Fouqueray P
Diabetes Obes Metab; 2021 Mar; 23(3):800-810. PubMed ID: 33275318
[TBL] [Abstract][Full Text] [Related]
19. [Imeglimin: features of the mechanism of action and potential benefits].
Kuznetsov KO; Saetova AA; Mahmutova EI; Bobrik AG; Bobrik DV; Nagaev IR; Khamitova AD; Arapieva AM
Probl Endokrinol (Mosk); 2022 Mar; 68(3):57-66. PubMed ID: 35841169
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and Biological Properties of Imeglimin Hydrochlo ride, A Novel Antidiabetic Agent: A Systematic Review.
Sultan J; Agarwal N; Sharma S
Curr Diabetes Rev; 2024; 20(5):e171023222286. PubMed ID: 37855361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
